Vasoplegic syndrome following cardiothoracic surgery – review of pathophysiology and update of treatment options (2020)

Peer-Reviewed Study · Busse LW, Barker N, Petersen C · February 4, 2020

Busse LW et al., 2020-02-04: Review of vasoplegic syndrome places methylene blue among vasoconstricting, catecholamine-sparing agents: it raises vascular smooth-muscle tone by inhibiting eNOS and guanylate cyclase, and is used after vasopressin in the authors' treatment algorithm.

the mechanism of action involves the inhibition of both eNOS and guanylate cyclase which work in tandem with sympathetic vasopressors to reduce vasodilation and improve hemodynamic stability

Busse LW et al., 2020-02-04: Review of vasoplegic syndrome places methylene blue among vasoconstricting, catecholamine-sparing agents: it raises vascular smooth-muscle tone by inhibiting eNOS and guanylate cyclase, and is used after vasopressin in the authors' treatment algorithm. Critical Care 2020;24:36. Type: narrative review. No patients. Funder/conflicts: not stated in the retrieved text. Quote is from the 'Methylene blue' subsection; preceding sentence: 'MB has been shown to increase vascular smooth muscle tone'. Study type: review.